Medical - Care Facilities
Compare Stocks
5 / 10Stock Comparison
AMS vs ARAY vs NNOX vs BLCO vs IART
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Devices
Medical - Devices
Medical - Instruments & Supplies
Medical - Devices
AMS vs ARAY vs NNOX vs BLCO vs IART — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Care Facilities | Medical - Devices | Medical - Devices | Medical - Instruments & Supplies | Medical - Devices |
| Market Cap | $13M | $35M | $115M | $5.67B | $1.06B |
| Revenue (TTM) | $29M | $429M | $12M | $5.21B | $1.64B |
| Net Income (TTM) | $-2M | $-46M | $-56M | $-219M | $-496M |
| Gross Margin | 25.0% | 26.8% | -98.8% | 55.9% | 39.6% |
| Operating Margin | -12.3% | -5.1% | -469.7% | 5.9% | 5.8% |
| Forward P/E | 6.1x | — | — | 20.1x | 5.8x |
| Total Debt | $23M | $176M | $7M | $5.37B | $2.03B |
| Cash & Equiv. | $11M | $57M | $39M | $383M | $235M |
AMS vs ARAY vs NNOX vs BLCO vs IART — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 22 | May 26 | Return |
|---|---|---|---|
| American Shared Hos… (AMS) | 100 | 86.5 | -13.5% |
| Accuray Incorporated (ARAY) | 100 | 14.1 | -85.9% |
| Nano-X Imaging Ltd. (NNOX) | 100 | 17.2 | -82.8% |
| Bausch + Lomb Corpo… (BLCO) | 100 | 93.5 | -6.5% |
| Integra LifeScience… (IART) | 100 | 21.6 | -78.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: AMS vs ARAY vs NNOX vs BLCO vs IART
Each card shows where this stock fits in a portfolio — not just who wins on paper.
AMS is the #2 pick in this set and the best alternative if income & stability and growth exposure is your priority.
- Dividend streak 0 yrs, beta -0.02
- Rev growth 32.9%, EPS growth 245.9%, 3Y rev CAGR 17.1%
- -4.7% 10Y total return vs BLCO's -20.5%
- 32.9% revenue growth vs IART's 1.5%
ARAY lags the leaders in this set but could rank higher in a more targeted comparison.
NNOX is the clearest fit if your priority is sleep-well-at-night and defensive.
- Lower volatility, beta 1.86, Low D/E 3.9%, current ratio 5.63x
- Beta 1.86, current ratio 5.63x
BLCO carries the broadest edge in this set and is the clearest fit for quality and stability.
- -4.2% margin vs NNOX's -452.8%
- Beta 1.39 vs ARAY's 2.42, lower leverage
- +39.5% vs ARAY's -78.4%
- -1.6% ROA vs NNOX's -31.6%, ROIC 1.2% vs -27.9%
IART ranks third and is worth considering specifically for value.
- Lower P/E (5.8x vs 20.1x)
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 32.9% revenue growth vs IART's 1.5% | |
| Value | Lower P/E (5.8x vs 20.1x) | |
| Quality / Margins | -4.2% margin vs NNOX's -452.8% | |
| Stability / Safety | Beta 1.39 vs ARAY's 2.42, lower leverage | |
| Dividends | Tie | None of these 5 stocks pay a meaningful dividend |
| Momentum (1Y) | +39.5% vs ARAY's -78.4% | |
| Efficiency (ROA) | -1.6% ROA vs NNOX's -31.6%, ROIC 1.2% vs -27.9% |
AMS vs ARAY vs NNOX vs BLCO vs IART — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
AMS vs ARAY vs NNOX vs BLCO vs IART — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
BLCO leads in 2 of 6 categories
ARAY leads 1 • AMS leads 0 • NNOX leads 0 • IART leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
BLCO leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
BLCO is the larger business by revenue, generating $5.2B annually — 423.3x NNOX's $12M. Profitability is closely matched — net margins range from -4.2% (BLCO) to -4.5% (NNOX). On growth, NNOX holds the edge at +13.7% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $29M | $429M | $12M | $5.2B | $1.6B |
| EBITDAEarnings before interest/tax | $2M | -$15M | -$46M | $724M | $209M |
| Net IncomeAfter-tax profit | -$2M | -$46M | -$56M | -$219M | -$496M |
| Free Cash FlowCash after capex | -$10M | -$28M | -$47M | $4M | -$10M |
| Gross MarginGross profit ÷ Revenue | +25.0% | +26.8% | -98.8% | +55.9% | +39.6% |
| Operating MarginEBIT ÷ Revenue | -12.3% | -5.1% | -4.7% | +5.9% | +5.8% |
| Net MarginNet income ÷ Revenue | -7.6% | -10.8% | -4.5% | -4.2% | -30.1% |
| FCF MarginFCF ÷ Revenue | -34.7% | -6.5% | -3.8% | +0.1% | -0.6% |
| Rev. Growth (YoY)Latest quarter vs prior year | +2.5% | -7.4% | +13.7% | +9.4% | +2.4% |
| EPS Growth (YoY)Latest quarter vs prior year | -56.7% | -6.1% | +8.7% | +66.7% | +81.8% |
Valuation Metrics
ARAY leads this category, winning 3 of 5 comparable metrics.
Valuation Metrics
On an enterprise value basis, AMS's 7.5x EV/EBITDA is more attractive than BLCO's 17.5x.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $13M | $35M | $115M | $5.7B | $1.1B |
| Enterprise ValueMkt cap + debt − cash | $25M | $154M | $83M | $10.7B | $2.9B |
| Trailing P/EPrice ÷ TTM EPS | 6.09x | -18.91x | -1.93x | -15.59x | -2.01x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | — | 20.10x | 5.77x |
| PEG RatioP/E ÷ EPS growth rate | 0.93x | — | — | — | — |
| EV / EBITDAEnterprise value multiple | 7.51x | 10.99x | — | 17.50x | 13.01x |
| Price / SalesMarket cap ÷ Revenue | 0.46x | 0.08x | 10.20x | 1.11x | 0.65x |
| Price / BookPrice ÷ Book value/share | 0.45x | 0.37x | 0.55x | 0.86x | 1.00x |
| Price / FCFMarket cap ÷ FCF | — | — | — | — | — |
Profitability & Efficiency
Evenly matched — ARAY and NNOX and BLCO each lead in 3 of 9 comparable metrics.
Profitability & Efficiency
BLCO delivers a -3.4% return on equity — every $100 of shareholder capital generates $-3 in annual profit, vs $-77 for ARAY. NNOX carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to ARAY's 2.17x. On the Piotroski fundamental quality scale (0–9), ARAY scores 6/9 vs BLCO's 3/9, reflecting solid financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -7.9% | -77.5% | -35.5% | -3.4% | -47.6% |
| ROA (TTM)Return on assets | -3.8% | -10.1% | -31.6% | -1.6% | -13.7% |
| ROICReturn on invested capital | -5.8% | +3.0% | -27.9% | +1.2% | +1.7% |
| ROCEReturn on capital employed | -6.4% | +2.8% | -28.4% | +1.6% | +2.2% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 6 | 4 | 3 | 5 |
| Debt / EquityFinancial leverage | 0.77x | 2.17x | 0.04x | 0.82x | 1.95x |
| Net DebtTotal debt minus cash | $12M | $119M | -$32M | $5.0B | $1.8B |
| Cash & Equiv.Liquid assets | $11M | $57M | $39M | $383M | $235M |
| Total DebtShort + long-term debt | $23M | $176M | $7M | $5.4B | $2.0B |
| Interest CoverageEBIT ÷ Interest expense | -1.35x | -1.86x | -379.29x | 0.71x | -10.36x |
Total Returns (Dividends Reinvested)
BLCO leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in BLCO five years ago would be worth $7,950 today (with dividends reinvested), compared to $605 for NNOX. Over the past 12 months, BLCO leads with a +39.5% total return vs ARAY's -78.4%. The 3-year compound annual growth rate (CAGR) favors BLCO at -4.5% vs ARAY's -56.6% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -4.3% | -65.5% | -37.8% | -4.1% | +12.9% |
| 1-Year ReturnPast 12 months | -27.4% | -78.4% | -64.4% | +39.5% | +6.5% |
| 3-Year ReturnCumulative with dividends | -28.0% | -91.8% | -89.2% | -13.0% | -73.1% |
| 5-Year ReturnCumulative with dividends | -41.1% | -93.9% | -93.9% | -20.5% | -81.7% |
| 10-Year ReturnCumulative with dividends | -4.7% | -94.5% | -96.1% | -20.5% | -63.0% |
| CAGR (3Y)Annualised 3-year return | -10.4% | -56.6% | -52.4% | -4.5% | -35.4% |
Risk & Volatility
Evenly matched — AMS and BLCO each lead in 1 of 2 comparable metrics.
Risk & Volatility
AMS is the less volatile stock with a -0.02 beta — it tends to amplify market swings less than ARAY's 2.42 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. BLCO currently trades 84.0% from its 52-week high vs ARAY's 14.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | -0.02x | 2.42x | 1.86x | 1.39x | 2.34x |
| 52-Week HighHighest price in past year | $3.11 | $2.10 | $5.86 | $18.92 | $16.49 |
| 52-Week LowLowest price in past year | $1.25 | $0.28 | $1.66 | $10.85 | $8.70 |
| % of 52W HighCurrent price vs 52-week peak | +64.6% | +14.0% | +30.0% | +84.0% | +82.2% |
| RSI (14)Momentum oscillator 0–100 | 63.8 | 58.4 | 38.5 | 46.9 | 75.9 |
| Avg Volume (50D)Average daily shares traded | 138K | 1.4M | 1.4M | 412K | 858K |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: NNOX as "Buy", BLCO as "Hold", IART as "Buy". Consensus price targets imply 922.7% upside for NNOX (target: $18) vs -11.5% for IART (target: $12).
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — | Buy | Hold | Buy |
| Price TargetConsensus 12-month target | — | — | $18.00 | $19.00 | $12.00 |
| # AnalystsCovering analysts | — | — | 5 | 16 | 26 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — | — |
| Dividend StreakConsecutive years of raises | 0 | — | — | — | 0 |
| Dividend / ShareAnnual DPS | — | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | 0.0% | +0.0% |
BLCO leads in 2 of 6 categories (Income & Cash Flow, Total Returns). ARAY leads in 1 (Valuation Metrics). 2 tied.
AMS vs ARAY vs NNOX vs BLCO vs IART: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is AMS or ARAY or NNOX or BLCO or IART a better buy right now?
For growth investors, American Shared Hospital Services (AMS) is the stronger pick with 32.
9% revenue growth year-over-year, versus 1. 5% for Integra LifeSciences Holdings Corporation (IART). American Shared Hospital Services (AMS) offers the better valuation at 6. 1x trailing P/E, making it the more compelling value choice. Analysts rate Nano-X Imaging Ltd. (NNOX) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — AMS or ARAY or NNOX or BLCO or IART?
On forward P/E, Integra LifeSciences Holdings Corporation is actually cheaper at 5.
8x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — AMS or ARAY or NNOX or BLCO or IART?
Over the past 5 years, Bausch + Lomb Corporation (BLCO) delivered a total return of -20.
5%, compared to -93. 9% for Nano-X Imaging Ltd. (NNOX). Over 10 years, the gap is even starker: AMS returned -4. 7% versus NNOX's -96. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — AMS or ARAY or NNOX or BLCO or IART?
By beta (market sensitivity over 5 years), American Shared Hospital Services (AMS) is the lower-risk stock at -0.
02β versus Accuray Incorporated's 2. 42β — meaning ARAY is approximately -15516% more volatile than AMS relative to the S&P 500. On balance sheet safety, Nano-X Imaging Ltd. (NNOX) carries a lower debt/equity ratio of 4% versus 2% for Accuray Incorporated — giving it more financial flexibility in a downturn.
05Which is growing faster — AMS or ARAY or NNOX or BLCO or IART?
By revenue growth (latest reported year), American Shared Hospital Services (AMS) is pulling ahead at 32.
9% versus 1. 5% for Integra LifeSciences Holdings Corporation (IART). On earnings-per-share growth, the picture is similar: American Shared Hospital Services grew EPS 245. 9% year-over-year, compared to -73. 6% for Integra LifeSciences Holdings Corporation. Over a 3-year CAGR, NNOX leads at 105. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — AMS or ARAY or NNOX or BLCO or IART?
American Shared Hospital Services (AMS) is the more profitable company, earning 7.
7% net margin versus -474. 3% for Nano-X Imaging Ltd. — meaning it keeps 7. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IART leads at 4. 2% versus -502. 9% for NNOX. At the gross margin level — before operating expenses — BLCO leads at 54. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is AMS or ARAY or NNOX or BLCO or IART more undervalued right now?
On forward earnings alone, Integra LifeSciences Holdings Corporation (IART) trades at 5.
8x forward P/E versus 20. 1x for Bausch + Lomb Corporation — 14. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NNOX: 922. 7% to $18. 00.
08Which pays a better dividend — AMS or ARAY or NNOX or BLCO or IART?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is AMS or ARAY or NNOX or BLCO or IART better for a retirement portfolio?
For long-horizon retirement investors, American Shared Hospital Services (AMS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.
02)). Accuray Incorporated (ARAY) carries a higher beta of 2. 42 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (AMS: -4. 7%, ARAY: -94. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between AMS and ARAY and NNOX and BLCO and IART?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: AMS is a small-cap high-growth stock; ARAY is a small-cap quality compounder stock; NNOX is a small-cap quality compounder stock; BLCO is a small-cap quality compounder stock; IART is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.